by Bennett Daviss
TECHNOLOGY	Growing Pains for Metabolomics The newest 'omic science is producing results – and more data than researchers know what to do with Email: Bennett Daviss - bdaviss@the-scientist.com The Scientist 2005, 19(8):25 Published   25 April 2005

When Merck & Co. withdrew the painkiller Vioxx from the market last September after the drug was linked to increased risks of heart attack and stroke, more than one metabolomics researcher shook their heads and thought, "If only ...."

(continued >>)

To continue reading this full article, you must be a subscriber to The Scientist.

You are only a few minutes away from unlimited access.

If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.

Subscribe to The Scientist to get unlimited access to our premium content

Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95.  Subscribe now.

The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.